Author

Mariana O. Diniz

University College LondonORCID 0000-0002-1961-0189Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

Alejandro Arenas‐PintoiD· 1 shared Alexandrine CarminatiiD· 1 shared Anandita Mathur· 1 shared Antonio CasaliD· 1 shared Avinash GuptaiD· 1 shared Brian Ritchie DavidsoniD· 1 shared Bryan WilliamsiD· 1 shared Charlotte ButtercaseiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Alejandro Arenas‐PintoORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Design and development of a SARS and MERS Combination Vaccine

Antonio Casal, Mohamed Deifallah Yousif, Samuel Ellis, Claire Mary Smith, Mariana O. Diniz, Bryan Williams, Paul Anthony Dalby, Gareth R. Williams, John Maxim Ward, Sudaxshina Murdan, Alejandro Arenas‐Pinto, Jose Alejandro Guevara-Patino, Delmiro Fernández-Reyes

This paper designs and tests a combination vaccine targeting SARS-CoV, SARS-CoV-2, and MERS using Spike proteins and adjuvants to enhance antibody responses and neutralizing capabilities.

bioRxiv · Oct 27, 2025 · PreprintImmunology

Splenic granulopoiesis and S100A9 drive resistance to checkpoint inhibitors conferred by liver metastases

Rebecca J. Lee, Steven Hooper, Laura J. Pallett, Mariana O. Diniz, Tate Mckinnon-Snell, Zoe Ramsden, Nicolas Rabas, Stefan Boeing, Oliver John Kennedy, Charlotte Buttercase, Gloryanne Aidoo-Micah, Gareth J. Price, Sarah C. Macfarlane, Sasha Bailey, Jessica E. Davies, , Erik A. Sahai

This study shows liver metastases reduce checkpoint inhibitor efficacy by increasing splenic granulopoiesis and S100A9hi neutrophils, which suppress T-cell responses, and demonstrates that targeting S100A9 restores efficacy.

bioRxiv · Sep 30, 2025 · PreprintImmunology